SCHEMBL5317439

SCHEMBL5317439

O=C(O)/C=C/c1nn(Cc2ccc(Cl)cc2Cl)c2cc([N+](=O)[O-])ccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
TSHR P16473 1/20 0.46
PMP22 Q01453 1/20 0.46
HIF1A Q16665 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ENPP2 Q13822 2/20 0.42
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
TBXA2R P21731 1/20 0.40
PTGFR P43088 1/20 0.40
PTGER3 P43115 1/20 0.40
PTGER2 P43116 1/20 0.40
PTGIR P43119 1/20 0.40
PTGDR Q13258 1/20 0.40
SLC22A12 Q96S37 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5317442 1.00 CYP1A2 (0.46) CYP1A2CYP3A4CYP2D6CYP2C9TSHR
SCHEMBL5317849 0.91 LMNA (0.46) CYP1A2CYP3A4CYP2D6CYP2C9TSHR
SCHEMBL5319966 0.91 ENPP2 (0.41) CYP1A2CYP3A4CYP2D6CYP2C9TSHR
SCHEMBL5319964 0.91 ENPP2 (0.41) CYP1A2CYP3A4CYP2D6CYP2C9TSHR
SCHEMBL5320310 0.91 ENPP2 (0.45) CYP1A2CYP3A4CYP2D6CYP2C9TSHR
SCHEMBL5320307 0.91 ENPP2 (0.45) CYP1A2CYP3A4CYP2D6CYP2C9TSHR
SCHEMBL5317847 0.91 LMNA (0.46) CYP1A2CYP3A4CYP2D6CYP2C9TSHR
SCHEMBL5319872 0.89 LMNA (0.42) CYP1A2CYP3A4CYP2D6CYP2C9TSHR
SCHEMBL5319875 0.89 LMNA (0.42) CYP1A2CYP3A4CYP2D6CYP2C9TSHR
SCHEMBL1046739 0.89 CYP1A2 (0.54) CYP1A2CYP3A4CYP2D6CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1786424-A2 LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT The University of Kansas (US) 2007-05-23 EP claimed
WO-2006023704-A2 LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT UNIVERSITY OF KANSAS (US) 2006-03-02 WO claimed
EP-2502624-A1 Lonidamine analogues and their use in male contraception and cancer treatment THE UNIVERSITY OF KANSAS (US) 2012-09-26 EP disclosed
EP-2502624-A1 Lonidamine analogues and their use in male contraception and cancer treatment THE UNIVERSITY OF KANSAS (US) 2012-09-26 EP disclosed